Lisata Therapeutics (LSTA) to be Acquired by Kuva Labs at $4.00 per Share, 180% Premium
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy LSTA?
Source: seekingalpha
- Acquisition Agreement: Lisata Therapeutics has entered into a binding term sheet with Kuva Labs, which plans to acquire the company for $4.00 per share in cash, with a definitive purchase agreement expected by February 27, 2026, reflecting strong confidence in the company's future.
- Significant Premium: The $4.00 per share offer represents an approximate 85% premium over Lisata's most recent closing price, and with the inclusion of two non-tradeable CVRs, the total premium reaches approximately 180%, indicating high market recognition of Lisata's future potential.
- Future Earnings Potential: Lisata shareholders will receive two non-tradeable CVRs, each worth $1.00 upon the return of Greater China rights to Certepetide from Qilu Pharmaceutical and upon Kuva filing an NDA or similar application, enhancing potential shareholder returns.
- Strategic Implications: This acquisition not only provides Lisata with financial backing but may also accelerate the market introduction of Certepetide, strengthening the company's competitive position in the biopharmaceutical sector and aligning with industry consolidation trends.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LSTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LSTA
About LSTA
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may involve violations of shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company's merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined company, with Halper Sadeh LLC assessing the fairness of the transaction and its impact on shareholders.
- Cash Acquisition Analysis: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable contingent value rights, raising concerns from Halper Sadeh LLC about whether this transaction serves the best interests of shareholders.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning approximately 80.3% of the combined entity, with Halper Sadeh LLC investigating the potential implications and protections for shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may infringe on shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company’s merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined entity, and Halper Sadeh LLC may seek increased consideration and additional disclosures.
- Cash Acquisition Scrutiny: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable rights, and Halper Sadeh LLC is assessing whether this transaction aligns with shareholder interests.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning about 80.3% of the combined company, with Halper Sadeh LLC potentially advocating for higher transaction consideration and additional shareholder benefits.
See More
Investor Rights Law Firm Investigates Multiple Companies
- SkyWater Transaction Investigation: Halper Sadeh LLC is investigating SkyWater Technology, Inc. (NASDAQ: SKYT) for its sale to IonQ at $15.00 in cash and $20.00 in IonQ common stock, potentially violating federal securities laws and fiduciary duties to shareholders.
- Nathan's Famous Sale Review: The firm is also scrutinizing Nathan’s Famous, Inc. (NASDAQ: NATH) for its sale to Smithfield Foods, Inc. at $102.00 per share in cash, which may impact shareholder rights.
- Sun Country Airlines Deal Issues: The sale of Sun Country Airlines Holdings, Inc. (NASDAQ: SNCY) to Allegiant Travel Company for 0.1557 shares of Allegiant common stock and $4.10 in cash per share is under investigation, with the firm potentially seeking increased compensation for shareholders.
- Lisata Therapeutics Transaction Focus: Lisata Therapeutics, Inc. (NASDAQ: LSTA) is being reviewed for its sale to Kuva Labs, Inc. at $4.00 per share in cash plus two non-tradeable contingent value rights, with the law firm offering legal support to shareholders.
See More
Investigations Launched into Multiple Company Acquisitions
- SkyWater Acquisition Investigation: SkyWater Technology is set to be acquired by IonQ for $35 per share, totaling approximately $1.8 billion; however, this price is below the company's 52-week high of $36.27, raising concerns about shareholder value.
- Nathan's Famous Deal Scrutiny: Nathan's Famous will be acquired by Smithfield Foods for $102 per share, representing an enterprise value of about $450 million, yet this price is below its 52-week high of $118.50, prompting questions about the board's fiduciary duties.
- Lisata Therapeutics Merger Issues: Lisata Therapeutics will be acquired by Kuva Labs for $4 per share, plus two non-tradeable rights, with investigations focusing on whether the board failed to conduct a fair process, potentially harming shareholder interests.
- Sun Country Airlines Acquisition Review: Sun Country Airlines will be acquired for 0.1557 shares of Allegiant stock and $4.10 in cash per share, implying a value of $18.89 per share, with investigations into whether the board breached its fiduciary duties to shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Nathan’s Famous, Inc. (NASDAQ: NATH) for potential violations related to its sale to Smithfield Foods, Inc. for $102.00 per share in cash, aiming to protect shareholder rights and seek increased compensation.
- Transaction Details: Penumbra, Inc. (NYSE: PEN) is being sold for $374.00 in cash or 3.8721 shares of Boston Scientific common stock, with Halper Sadeh LLC potentially advocating for more information and compensation to ensure transaction transparency for shareholders.
- Legal Rights: RAPT Therapeutics, Inc. (NASDAQ: RAPT) is selling to GSK plc for $58.00 per share, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and options, ensuring their interests are safeguarded in the transaction.
- Shareholder Support: Lisata Therapeutics, Inc. (NASDAQ: LSTA) is being sold for $4.00 per share in cash plus two non-tradeable rights, with Halper Sadeh LLC offering contingent fee legal services to help shareholders secure their rightful interests in the potential transaction.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde & Associates is investigating the acquisition of Penumbra, Inc. by Boston Scientific Corporation, where shareholders are expected to receive either $374 in cash or 3.8721 shares of Boston Scientific, highlighting a commitment to shareholder rights.
- RAPT Transaction Details: In the sale of RAPT Therapeutics, Inc. to GSK plc, shareholders are anticipated to receive $58 in cash per share, reflecting positive market expectations regarding the transaction's value.
- Nathan's Famous Acquisition: Nathan’s Famous, Inc. is set to receive $102 in cash per share from Smithfield Foods, indicating a direct financial benefit to shareholders from this acquisition.
- Lisata Transaction Terms: Lisata Therapeutics, Inc. shareholders will receive $4 in cash per share along with potential contingent value rights in the sale to Smithfield Foods, suggesting future revenue opportunities for investors.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may involve violations of shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company's merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined company, with Halper Sadeh LLC assessing the fairness of the transaction and its impact on shareholders.
- Cash Acquisition Analysis: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable contingent value rights, raising concerns from Halper Sadeh LLC about whether this transaction serves the best interests of shareholders.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning approximately 80.3% of the combined entity, with Halper Sadeh LLC investigating the potential implications and protections for shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may infringe on shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company’s merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined entity, and Halper Sadeh LLC may seek increased consideration and additional disclosures.
- Cash Acquisition Scrutiny: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable rights, and Halper Sadeh LLC is assessing whether this transaction aligns with shareholder interests.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning about 80.3% of the combined company, with Halper Sadeh LLC potentially advocating for higher transaction consideration and additional shareholder benefits.
See More
Investor Rights Law Firm Investigates Multiple Companies
- SkyWater Transaction Investigation: Halper Sadeh LLC is investigating SkyWater Technology, Inc. (NASDAQ: SKYT) for its sale to IonQ at $15.00 in cash and $20.00 in IonQ common stock, potentially violating federal securities laws and fiduciary duties to shareholders.
- Nathan's Famous Sale Review: The firm is also scrutinizing Nathan’s Famous, Inc. (NASDAQ: NATH) for its sale to Smithfield Foods, Inc. at $102.00 per share in cash, which may impact shareholder rights.
- Sun Country Airlines Deal Issues: The sale of Sun Country Airlines Holdings, Inc. (NASDAQ: SNCY) to Allegiant Travel Company for 0.1557 shares of Allegiant common stock and $4.10 in cash per share is under investigation, with the firm potentially seeking increased compensation for shareholders.
- Lisata Therapeutics Transaction Focus: Lisata Therapeutics, Inc. (NASDAQ: LSTA) is being reviewed for its sale to Kuva Labs, Inc. at $4.00 per share in cash plus two non-tradeable contingent value rights, with the law firm offering legal support to shareholders.
See More
Investigations Launched into Multiple Company Acquisitions
- SkyWater Acquisition Investigation: SkyWater Technology is set to be acquired by IonQ for $35 per share, totaling approximately $1.8 billion; however, this price is below the company's 52-week high of $36.27, raising concerns about shareholder value.
- Nathan's Famous Deal Scrutiny: Nathan's Famous will be acquired by Smithfield Foods for $102 per share, representing an enterprise value of about $450 million, yet this price is below its 52-week high of $118.50, prompting questions about the board's fiduciary duties.
- Lisata Therapeutics Merger Issues: Lisata Therapeutics will be acquired by Kuva Labs for $4 per share, plus two non-tradeable rights, with investigations focusing on whether the board failed to conduct a fair process, potentially harming shareholder interests.
- Sun Country Airlines Acquisition Review: Sun Country Airlines will be acquired for 0.1557 shares of Allegiant stock and $4.10 in cash per share, implying a value of $18.89 per share, with investigations into whether the board breached its fiduciary duties to shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Nathan’s Famous, Inc. (NASDAQ: NATH) for potential violations related to its sale to Smithfield Foods, Inc. for $102.00 per share in cash, aiming to protect shareholder rights and seek increased compensation.
- Transaction Details: Penumbra, Inc. (NYSE: PEN) is being sold for $374.00 in cash or 3.8721 shares of Boston Scientific common stock, with Halper Sadeh LLC potentially advocating for more information and compensation to ensure transaction transparency for shareholders.
- Legal Rights: RAPT Therapeutics, Inc. (NASDAQ: RAPT) is selling to GSK plc for $58.00 per share, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and options, ensuring their interests are safeguarded in the transaction.
- Shareholder Support: Lisata Therapeutics, Inc. (NASDAQ: LSTA) is being sold for $4.00 per share in cash plus two non-tradeable rights, with Halper Sadeh LLC offering contingent fee legal services to help shareholders secure their rightful interests in the potential transaction.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde & Associates is investigating the acquisition of Penumbra, Inc. by Boston Scientific Corporation, where shareholders are expected to receive either $374 in cash or 3.8721 shares of Boston Scientific, highlighting a commitment to shareholder rights.
- RAPT Transaction Details: In the sale of RAPT Therapeutics, Inc. to GSK plc, shareholders are anticipated to receive $58 in cash per share, reflecting positive market expectations regarding the transaction's value.
- Nathan's Famous Acquisition: Nathan’s Famous, Inc. is set to receive $102 in cash per share from Smithfield Foods, indicating a direct financial benefit to shareholders from this acquisition.
- Lisata Transaction Terms: Lisata Therapeutics, Inc. shareholders will receive $4 in cash per share along with potential contingent value rights in the sale to Smithfield Foods, suggesting future revenue opportunities for investors.
See More
